DE60018782D1 - Tyrosin kinase inhibitoren - Google Patents

Tyrosin kinase inhibitoren

Info

Publication number
DE60018782D1
DE60018782D1 DE60018782T DE60018782T DE60018782D1 DE 60018782 D1 DE60018782 D1 DE 60018782D1 DE 60018782 T DE60018782 T DE 60018782T DE 60018782 T DE60018782 T DE 60018782T DE 60018782 D1 DE60018782 D1 DE 60018782D1
Authority
DE
Germany
Prior art keywords
tyrosine kinase
kinase inhibitors
compounds
angiogenesis
atherosclerosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60018782T
Other languages
English (en)
Other versions
DE60018782T2 (de
Inventor
E Fraley
R Hambaugh
W Hungate
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of DE60018782D1 publication Critical patent/DE60018782D1/de
Application granted granted Critical
Publication of DE60018782T2 publication Critical patent/DE60018782T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
DE60018782T 1999-10-19 2000-10-16 Tyrosin kinase inhibitoren Expired - Lifetime DE60018782T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16036299P 1999-10-19 1999-10-19
US160362P 1999-10-19
PCT/US2000/028641 WO2001028993A2 (en) 1999-10-19 2000-10-16 Tyrosine kinase inhibitors

Publications (2)

Publication Number Publication Date
DE60018782D1 true DE60018782D1 (de) 2005-04-21
DE60018782T2 DE60018782T2 (de) 2006-04-06

Family

ID=22576564

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60018782T Expired - Lifetime DE60018782T2 (de) 1999-10-19 2000-10-16 Tyrosin kinase inhibitoren

Country Status (9)

Country Link
US (1) US6479512B1 (de)
EP (1) EP1226119B1 (de)
JP (1) JP2003512353A (de)
AT (1) ATE290865T1 (de)
AU (1) AU778042B2 (de)
CA (1) CA2387840A1 (de)
DE (1) DE60018782T2 (de)
ES (1) ES2235970T3 (de)
WO (1) WO2001028993A2 (de)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1226119B1 (de) * 1999-10-19 2005-03-16 MERCK & CO. INC. Tyrosin kinase inhibitoren
AU2001277731A1 (en) * 2000-08-09 2002-02-18 Welfide Corporation Fused bicyclic amide compounds and medicinal use thereof
ATE448226T1 (de) 2000-09-01 2009-11-15 Novartis Vaccines & Diagnostic Aza heterocyclische derivate und ihre therapeutische verwendung
DE60132937T2 (de) * 2000-09-11 2009-02-12 Novartis Vaccines and Diagnostics, Inc., Emeryville Verfahren zur Herstellung von Benzimidazol-2-yl -Chinolinonderivaten
US20030028018A1 (en) * 2000-09-11 2003-02-06 Chiron Coporation Quinolinone derivatives
US6544962B1 (en) * 2000-11-02 2003-04-08 Matrix Pharmaceutical, Inc. Methods for treating cellular proliferative disorders
NZ516873A (en) * 2001-02-12 2003-11-28 Warner Lambert Co Compositions containing retinoids and erb inhibitors and their use in inhibiting retinoid skin damage
CN1700917B (zh) * 2001-05-16 2010-04-28 诺瓦提斯公司 含n-(5-{4-[4-甲基-(1-哌嗪基)甲基]-苯甲酰氨基}-2-甲基苯基)-4-(3-吡啶基)-2-嘧啶-胺和化疗药的联合形式
US7642278B2 (en) 2001-07-03 2010-01-05 Novartis Vaccines And Diagnostics, Inc. Indazole benzimidazole compounds
WO2003024969A1 (en) * 2001-09-14 2003-03-27 Merck & Co., Inc. Tyrosine kinase inhibitors
GB0124848D0 (en) * 2001-10-16 2001-12-05 Celltech R&D Ltd Chemical compounds
WO2003035618A2 (en) * 2001-10-24 2003-05-01 Iconix Pharmaceuticals, Inc. Modulators of phosphoinositide 3-kinase
WO2003035008A2 (en) * 2001-10-26 2003-05-01 Oxigene, Inc. Functionalized stilbene derivatives as improved vascular targeting agents
US6822097B1 (en) 2002-02-07 2004-11-23 Amgen, Inc. Compounds and methods of uses
AU2003249540A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc Fused bicyclic metalloproteinase inhibitors
DE10238002A1 (de) * 2002-08-20 2004-03-04 Merck Patent Gmbh Benzimidazolderivate
JP4613130B2 (ja) * 2002-08-23 2011-01-12 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド ベンゾイミダゾールキノリノンおよびそれらの使用
US20050256157A1 (en) * 2002-08-23 2005-11-17 Chiron Corporation Combination therapy with CHK1 inhibitors
US7825132B2 (en) * 2002-08-23 2010-11-02 Novartis Vaccines And Diagnostics, Inc. Inhibition of FGFR3 and treatment of multiple myeloma
AU2003275282A1 (en) * 2002-09-30 2004-04-23 Bristol-Myers Squibb Company Novel tyrosine kinase inhibitors
GB0222912D0 (en) * 2002-10-03 2002-11-13 Astrazeneca Ab Novel process and intermediates
GB0222909D0 (en) 2002-10-03 2002-11-13 Astrazeneca Ab Novel process and intermediates
JP2006512313A (ja) * 2002-10-31 2006-04-13 アムジェン インコーポレイテッド 抗炎症剤
US20040091455A1 (en) * 2002-10-31 2004-05-13 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
US7838527B2 (en) * 2002-11-13 2010-11-23 Novartis Vaccines And Diagnostics, Inc. Methods of treating cancer and related methods
WO2004050033A2 (en) * 2002-12-02 2004-06-17 Arqule, Inc. Method of treating cancers
BRPI0410439A (pt) * 2003-05-19 2006-06-06 Irm Llc compostos e composições imunossupressoras
EP2287326A1 (de) 2003-08-08 2011-02-23 Arriva Pharmaceuticals, Inc. Verfahren zur Protein-Produktion in Hefe
MXJL06000006A (es) * 2003-08-22 2006-05-04 Avanir Pharmaceuticals Derivados de naftiridina sustituidos como inhibidores del factor inhibidor de la migracion de macrofagos y su uso en el tratamiento de enfermedades en el hombre.
CA2543820C (en) * 2003-11-07 2012-07-10 Chiron Corporation Methods for synthesizing quinolinone compounds
WO2005054183A2 (en) * 2003-12-01 2005-06-16 The Scripps Research Institute Quinolinone based protein kinase inhibitors
US7875624B2 (en) * 2004-02-20 2011-01-25 Novartis Vaccines And Diagnostics, Inc. Modulating and measuring cellular adhesion
EP1737499A4 (de) 2004-03-09 2009-07-22 Arriva Pharmaceuticals Inc Behandlung von chronisch obstruktiver lungenerkrankung durch inhalation von niedrigen dosen eines proteasehemmers
US20060183750A1 (en) 2005-01-27 2006-08-17 Chiron Corporation Treatment of metastasized tumors
US7960548B2 (en) * 2005-04-29 2011-06-14 The Ohio State University Research Foundation Keratinocyte growth factor receptor—tyrosine specific inhibitors for the prevention of cancer metastatis
KR101319122B1 (ko) 2005-05-13 2013-10-23 노파르티스 아게 약물 저항성 암을 치료하는 방법
JP5545925B2 (ja) 2005-05-17 2014-07-09 ノバルティス アーゲー ヘテロ環化合物の合成方法
CN101218228A (zh) * 2005-05-23 2008-07-09 诺瓦提斯公司 4-氨基-5-氟-3-[6-(4-甲基哌嗪-1-基)-1h-苯并咪唑-2-基]-1h-喹啉-2-酮乳酸盐的结晶和其它形式
US8658633B2 (en) * 2006-02-16 2014-02-25 Massachusetts Eye And Ear Infirmary Methods and compositions for treating conditions of the eye
CN100488960C (zh) * 2006-03-09 2009-05-20 中国药科大学 2-位取代的喹诺酮类化合物及其在制药中的应用
EP2004193A2 (de) * 2006-03-13 2008-12-24 Merck & Co., Inc. Ophthalmische zusammensetzungen zur behandlung von augenhochdruck
US8246966B2 (en) * 2006-08-07 2012-08-21 University Of Georgia Research Foundation, Inc. Trypanosome microsome system and uses thereof
WO2008066755A2 (en) 2006-11-22 2008-06-05 University Of Georgia Research Foundation, Inc. Tyrosine kinase inhibitors as anti-kinetolastid and anti-apicomplexan agents
US8492374B2 (en) * 2009-04-29 2013-07-23 Industrial Technology Research Institute Azaazulene compounds
JP5589077B2 (ja) 2009-07-20 2014-09-10 ブリストル−マイヤーズ スクイブ カンパニー 増殖性疾患の相乗的処置のための抗ｃｔｌａ４抗体と多様な治療レジメンとの組み合わせ
WO2011050069A1 (en) 2009-10-20 2011-04-28 Prometheus Laboratories Inc. Proximity-mediated assays for detecting oncogenic fusion proteins
GB201016761D0 (en) * 2010-10-05 2010-11-17 Syngenta Ltd Herbicidal compounds
KR101511889B1 (ko) 2011-02-17 2015-04-13 네스텍 소시에테아노님 여과에 의해 백혈구 및 종양 세포를 단리하는 장비 및 방법
US8921533B2 (en) 2011-07-25 2014-12-30 Chromatin Technologies Glycosylated valproic acid analogs and uses thereof
EP2844282B1 (de) 2012-05-04 2019-06-12 Pfizer Inc Prostata-assoziierte antigene und immuntherapieschemata auf impfstoffbasis
WO2014015905A1 (en) 2012-07-26 2014-01-30 Glaxo Group Limited 2 - (azaindol- 2 -yl) benz imidazoles as pad4 inhibitors
CA2897651C (en) 2013-01-10 2021-09-21 Pulmokine, Inc. Non-selective kinase inhibitors
CN113683695A (zh) 2013-08-02 2021-11-23 辉瑞公司 抗cxcr4抗体及抗体-药物缀合物
CA2926793C (en) 2013-10-11 2022-11-22 Lawrence S. ZISMAN Spray-dry formulations for treating pulmonary arterial hypertension
ES2708030T3 (es) 2014-10-20 2019-04-08 Inst Nat Sante Rech Med Métodos para explorar a un individuo en busca de un cáncer
ES2764299T3 (es) 2014-12-09 2020-06-02 Inst Nat Sante Rech Med Anticuerpos monoclonales humanos contra AXL
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
CA2989684A1 (en) * 2015-06-25 2016-12-29 University Health Network Hpk1 inhibitors and methods of using same
JP2018525029A (ja) 2015-07-07 2018-09-06 インセルム（インスティチュート ナショナル デ ラ サンテ エ デ ラ リシェルシェ メディカル） ミオシン１８ａに対する特異性を有する抗体およびその使用
JP6791951B2 (ja) 2015-08-27 2020-11-25 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 肺ガンを患っている患者の生存時間を予測するための方法
WO2017055327A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of endothelial cells in a tissue sample
WO2017055322A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of neutrophils in a tissue sample
WO2017055324A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of cells of monocytic origin in a tissue sample
WO2017055326A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of myeloid dendritic cells in a tissue sample
CN105622574B (zh) * 2016-02-04 2018-12-25 桂林医学院 3-苯并咪唑-2(1h)-喹啉酮衍生物及其制备方法和应用
CN105732576B (zh) * 2016-02-04 2018-08-28 桂林医学院 2-氯-3-(1h-苯并咪唑-2-基)-喹啉衍生物其制备方法和应用
BR112018067525A2 (pt) 2016-02-26 2019-02-05 Centre Nat Rech Scient anticorpos tendo especificidade para o btla e seus usos
AU2017270234B2 (en) 2016-05-25 2023-11-23 Assistance Publique-Hôpitaux De Paris (Aphp) Methods and compositions for treating cancers
WO2018011166A2 (en) 2016-07-12 2018-01-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of myeloid dendritic cells in a tissue sample
EP3491022A1 (de) 2016-07-29 2019-06-05 Institut National de la Sante et de la Recherche Medicale (INSERM) Antikörper gegen tumor-assoziierte makrophagen und verwendungen davon
FR3055331B1 (fr) * 2016-08-31 2020-03-06 Adpuerivitam Modulateurs de recepteurs nmda, compositions les comprenant et utilisation de ces composes dans le traitement de maladies impliquant le systeme nerveux central
MD3529262T2 (ro) 2016-10-21 2022-01-31 Inst Nat Sante Rech Med Metode pentru promovarea răspunsului celulelor T
CN110087653A (zh) 2016-10-27 2019-08-02 普尔莫凯恩股份有限公司 用于治疗肺高血压的组合疗法
US20190345500A1 (en) 2016-11-14 2019-11-14 |Nserm (Institut National De La Santé Et De La Recherche Médicale) Methods and pharmaceutical compositions for modulating stem cells proliferation or differentiation
CN110392697A (zh) 2017-03-02 2019-10-29 国家医疗保健研究所 对nectin-4具有特异性的抗体及其用途
WO2018185516A1 (en) 2017-04-05 2018-10-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating cardiovascular toxicity induced by anti-cancer therapy
WO2018189403A1 (en) 2017-04-14 2018-10-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of cancer
EP3624798A1 (de) 2017-05-18 2020-03-25 Institut National de la Sante et de la Recherche Medicale (INSERM) Verfahren und pharmazeutische zusammensetzungen zur behandlung von mastzellenerkrankungen
WO2019072888A1 (en) 2017-10-11 2019-04-18 INSERM (Institut National de la Santé et de la Recherche Médicale) METHODS OF PREDICTING THE THERAPEUTIC RESPONSE IN HEPATOCELLULAR CANCER
WO2019072885A1 (en) 2017-10-11 2019-04-18 INSERM (Institut National de la Santé et de la Recherche Médicale) MAGNETIC NANOPARTICLES FOR THE TREATMENT OF CANCER
KR20200111168A (ko) 2017-11-24 2020-09-28 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 암 치료를 위한 방법 및 조성물
EP3720974A1 (de) 2017-12-07 2020-10-14 Institut National de la Sante et de la Recherche Medicale (INSERM) Verfahren zum screening eines patienten auf einen krebs
EP3775206A1 (de) 2018-03-28 2021-02-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Verfahren und pharmazeutische zusammensetzungen zur behandlung von krebs
EP3775908A1 (de) 2018-04-13 2021-02-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Verfahren zur vorhersage des ergebnisses und der behandlung von patienten mit prostatakrebs oder brustkrebs
WO2019211369A1 (en) 2018-05-03 2019-11-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating cancer
WO2019211370A1 (en) 2018-05-03 2019-11-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating cancer
JP2021526161A (ja) 2018-05-30 2021-09-30 マショーヴァー, デイビィッドMACHOVER, David 癌治療のための方法及び医薬組成物
WO2019234221A1 (en) 2018-06-08 2019-12-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for stratification and treatment of a patient suffering from chronic lymphocytic leukemia
WO2020030634A1 (en) 2018-08-06 2020-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating cancers
WO2020053122A1 (en) 2018-09-10 2020-03-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination of her2/neu antibody with heme for treating cancer
KR20210125471A (ko) 2018-10-05 2021-10-18 안나푸르나 바이오, 인코포레이티드 Apj 수용체 활성과 관련된 병태를 치료하기 위한 화합물 및 조성물
US20220098674A1 (en) 2019-02-13 2022-03-31 Inserm (Institut National De La Santé Et Dr La Recherch Médicale) Methods and compositions for selecting a cancer treatment in a subject suffering from cancer
JP2022523544A (ja) 2019-03-06 2022-04-25 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Ｃｍｍｒｄの診断方法
US20220251232A1 (en) 2019-05-20 2022-08-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Novel anti-cd25 antibodies
WO2021023650A1 (en) 2019-08-02 2021-02-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for screening a subject for a cancer
EP3800201A1 (de) 2019-10-01 2021-04-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Cd28h-stimulierung verbessert nk-zellen-abtötungsaktivitäten
US20230040928A1 (en) 2019-12-09 2023-02-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies having specificity to her4 and uses thereof
EP4149558A1 (de) 2020-05-12 2023-03-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Neues verfahren zur behandlung von kutanen t-zell-lymphomen und tfh-abgeleiteten lymphomen
WO2022101463A1 (en) 2020-11-16 2022-05-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of the last c-terminal residues m31/41 of zikv m ectodomain for triggering apoptotic cell death
WO2022162162A1 (en) 2021-01-29 2022-08-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Method to diagnose msi cancer
US20220389104A1 (en) 2021-05-28 2022-12-08 Ose Immunotherapeutics Method for Treating CD127-Positive Cancers by Administering an Anti-CD127 Agent
WO2024052503A1 (en) 2022-09-08 2024-03-14 Institut National de la Santé et de la Recherche Médicale Antibodies having specificity to ltbp2 and uses thereof
WO2024061930A1 (en) 2022-09-22 2024-03-28 Institut National de la Santé et de la Recherche Médicale New method to treat and diagnose peripheral t-cell lymphoma (ptcl)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2108120T3 (es) * 1991-05-10 1997-12-16 Rhone Poulenc Rorer Int Compuestos bis arilicos y heteroarilicos mono- y biciclicos que inhiben tirosina quinasa receptora de egf y/o pdgf.
KR100567649B1 (ko) * 1996-09-25 2006-04-05 아스트라제네카 유케이 리미티드 혈관 내피 성장 인자와 같은 성장 인자의 효과를 억제하는 퀴놀린 유도체
ES2342240T3 (es) 1998-08-11 2010-07-02 Novartis Ag Derivados de isoquinolina con actividad que inhibe la angiogenia.
EP1226119B1 (de) * 1999-10-19 2005-03-16 MERCK & CO. INC. Tyrosin kinase inhibitoren

Also Published As

Publication number Publication date
JP2003512353A (ja) 2003-04-02
AU778042B2 (en) 2004-11-11
WO2001028993A2 (en) 2001-04-26
ES2235970T3 (es) 2005-07-16
CA2387840A1 (en) 2001-04-26
EP1226119B1 (de) 2005-03-16
ATE290865T1 (de) 2005-04-15
EP1226119A2 (de) 2002-07-31
AU1091301A (en) 2001-04-30
DE60018782T2 (de) 2006-04-06
EP1226119A4 (de) 2003-04-09
US6479512B1 (en) 2002-11-12
WO2001028993A3 (en) 2001-09-13

Similar Documents

Publication Publication Date Title
ATE309241T1 (de) Tyrosin kinase inhibitoren
DE60018782D1 (de) Tyrosin kinase inhibitoren
ATE368457T1 (de) Tyrosinkinase inhibitoren
YU28602A (sh) Inhibitori tirozin kinaze
DE60318198D1 (de) Tyrosinkinase-hemmer
DE60208792D1 (de) Tyrosin-kinase inhibitoren
WO2002045652A3 (en) Tyrosine kinase inhibitors
WO2003037252A3 (en) Tyrosine kinase inhibitors
AU2687702A (en) Orally active salts with tyrosine kinase activity
WO2004052315A3 (en) Tyrosine kinase inhibitors
WO2004052286A3 (en) Tyrosine kinase inhibitors
WO2003088900A3 (en) Solid forms of salts with tyrosine kinase activity
WO2004041164A3 (en) Kinase inhibitors
DE60231439D1 (de) Mitotische kinesinhemmer
DE60234278D1 (de) Mitotische kinesin-hemmer
WO2003020699A3 (en) Tyrosine kinase inhibitors
WO2003015717A3 (en) Tyrosine kinase inhibitors
MXPA02010759A (es) Derivados del acido (2-oxindol-3-ilidenil) acetico y su uso como inhibidores de la proteina quinasa.
ATE320255T1 (de) Tie2 rezeptor-kinase-inhibitoren zur behandlung von angiogenen erkrankungen
ECSP003729A (es) Inhibidores de la tirosina quinasa
ATE540951T1 (de) Substituierte 7,8-dihydro-1h-pyrimidoä4,5- büdiazepin-4-amine als kinase inhibitoren

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: MERCK & CO., INC., RAHWAY, N.J., US